Immunome, Inc. (NASDAQ:IMNM) Given Consensus Rating of "Buy" by Analysts

Key Points

• Immunome, Inc. (NASDAQ:IMNM) has received an average analyst rating of "Buy" with a 12-month price target of $23.20 from ten different ratings firms.
• The stock recently traded up 14.2%, opening at $11.59, while the company has a market cap of $1.01 billion.
• Immunome recently reported earnings of ($0.50) per share, exceeding analyst estimates, and generated $4.02 million in revenue during the last quarter.

Immunome, Inc. (NASDAQ:IMNM - Get Free Report) has been given an average rating of "Buy" by the ten ratings firms that are currently covering the stock, MarketBeat Ratings reports. Ten equities research analysts have rated the stock with a buy recommendation. The average 12-month price target among analysts that have updated their coverage on the stock in the last year is $23.20.

IMNM has been the subject of a number of research analyst reports. Guggenheim reaffirmed a "buy" rating and issued a $25.00 target price on shares of Immunome in a research note on Monday, August 25th. Evercore ISI initiated coverage on shares of Immunome in a research note on Friday, August 22nd. They issued an "outperform" rating and a $18.00 target price for the company. Craig Hallum assumed coverage on shares of Immunome in a research note on Friday, September 5th. They issued a "buy" rating and a $26.00 target price for the company. Wedbush reiterated an "outperform" rating and set a $21.00 price target on shares of Immunome in a research report on Thursday, September 18th. Finally, The Goldman Sachs Group assumed coverage on shares of Immunome in a research report on Monday. They set a "buy" rating and a $26.00 price target for the company.

Immunome Trading Up 14.2%

Shares of NASDAQ IMNM opened at $11.59 on Friday. Immunome has a 1-year low of $5.15 and a 1-year high of $15.20. The company has a market cap of $1.01 billion, a PE ratio of -3.76 and a beta of 1.92. The company has a 50-day moving average of $10.12 and a two-hundred day moving average of $8.90.

Immunome (NASDAQ:IMNM - Get Free Report) last announced its earnings results on Wednesday, August 6th. The company reported ($0.50) earnings per share for the quarter, topping analysts' consensus estimates of ($0.52) by $0.02. Immunome had a negative net margin of 1,687.08% and a negative return on equity of 76.10%. The company had revenue of $4.02 million during the quarter, compared to the consensus estimate of $1.03 million. As a group, equities research analysts forecast that Immunome will post -2.21 earnings per share for the current year.

Institutional Investors Weigh In On Immunome

Institutional investors have recently modified their holdings of the business. BNP Paribas Financial Markets grew its position in shares of Immunome by 81.8% during the 2nd quarter. BNP Paribas Financial Markets now owns 6,464 shares of the company's stock worth $60,000 after buying an additional 2,909 shares during the period. Tower Research Capital LLC TRC grew its position in shares of Immunome by 121.2% during the 2nd quarter. Tower Research Capital LLC TRC now owns 6,938 shares of the company's stock worth $65,000 after buying an additional 3,802 shares during the period. ANTIPODES PARTNERS Ltd acquired a new stake in shares of Immunome during the 1st quarter worth approximately $95,000. Brighton Jones LLC acquired a new position in Immunome during the second quarter valued at approximately $98,000. Finally, KLP Kapitalforvaltning AS grew its holdings in Immunome by 140.8% during the first quarter. KLP Kapitalforvaltning AS now owns 17,100 shares of the company's stock valued at $115,000 after purchasing an additional 10,000 shares during the period. Institutional investors and hedge funds own 44.58% of the company's stock.

About Immunome

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.